Voloridge Investment Management
MRSN

Voloridge Investment Management’s Mersana Therapeutics MRSN Stock Holding History

Voloridge Investment Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,009
Closed -$441K – 1523
2022
Q4 		$441K Sell
3,009
-170
-5% -$28.7K ﹤0.01% 1293
2022
Q3 		$537K Buy
+3,179
New +$517K ﹤0.01% 1251
2022
Q1 		– Sell
-3,385
Closed -$526K – 1585
2021
Q4 		$526K Sell
3,385
-473
-12% -$92K ﹤0.01% 1402
2021
Q3 		$910K Buy
+3,858
New +$1.13M 0.01% 1310

Other funds holding MRSN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Voloridge Investment Management's MRSN Position: Q1 2023 in Review

Voloridge Investment Management sold out of Mersana Therapeutics (MRSN) in Q1 2023, closing a stake of 3,009 shares — an estimated $441K sold.

Voloridge Investment Management first reported a position in MRSN in Q3 2021 and held it in 4 quarters. The position peaked at $910K in Q3 2021. 157 funds tracked by Wall St. Rank hold MRSN as of Q1 2023.

  • Voloridge Investment Management reported no remaining Mersana Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Voloridge Investment Management sold 3,009 Mersana Therapeutics shares in Q1 2023, an estimated $441K.
  • Voloridge Investment Management first reported a position in Mersana Therapeutics in Q3 2021 and held it in 4 quarters.
  • Voloridge Investment Management's Mersana Therapeutics position peaked at $910K in Q3 2021.
  • 157 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2023.

Based on Voloridge Investment Management's 13F filing for Q1 2023, filed 15 May 2023.